Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of V505 HPV vaccine formulations versus Gardasil in healthy women aged 16 to 26 years
2017-000108-42Phase 2
- Sponsor
- Merck & Co.
- Start
- Jan 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of V505 and qHPV vaccine in human papillomavirus infection (4 arms), sponsored by Merck & Co. Primary endpoints: Tolerability of V505 and Safety endpoints.
02
Drugs
V505qHPV vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2017-000108-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000108-42.